LC Labs/P-7890 Purvalanol A, Free Base, >99%/P-7890/25 mg
市场价：
¥1780.00
美元价：
1068.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
- Purvalanol A is a cell-permeable, potent, and selective cyclin-dependent kinase (CDK) inhibitor. It inhibited CDK kinases with IC50 values of 4 nM for CDC2/cyclin B, 70 nM for CDK2/cyclin A, 35 nM for CDK2/cyclin E, 75 nM for CDK5/p35, and 850 nM for CDK4/cyclin D1. Gray N.S., et al. “Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors.” Science 281: 533-538 (1998).
- Purvalanol A inhibited radiation-induced CDC2 kinase activity and induced apoptosis by increasing the levels of active fragments of caspase 3. Lizuka D., et al. “Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays.” Radiat. Res. 167: 563-571 (2007).
- Purvalanol A prevented hippocampal proliferation in a time- and concentration -dependent manner. Mackowiak M., et al. “Purvalanol A, inhibitor of cyclin-dependent kinases attenuates proliferation of cells in the dentate gyrus of the adult rat hippocampus.” Pharmacol. Rep. 57: 845-849 (2005)
- Purvalanol A arrested cells at the G(2)-M phase and induced apoptosis in a concentration-dependent manner. It also concomitantly down-regulated the antiapoptotic protein survivin, a member of the inhibitors of apoptosis protein family. Pennati M., et al. “Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.” Mol. Cancer Ther. 4: 1328-1337 (2005).
- In synchronized cells, purvalanol A arrested cells in the G1 and G2 phases, but did not prevent DNA synthesis in S-phase cells. After mouse fibroblasts and human cancer cell lines were incubated with purvalanol A for 24 hr, inhibition of cell proliferation and cell death were observed. Villerbu N., et al. “Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities.” Int. J. Cancer 97: 761-769 (2002).
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
C19H25ClN6O
[212844-53-6]
品牌介绍
LC Laboratories 公司提供信号转导，调节蛋白亚细胞定位试剂（抗生素）产品蛋白抑制剂产品。LC Laboratories（LC Labs）公司成立于1980年，一直专注于信号转导，肿瘤以及其他临床前试剂的研究和生产，主要提供抗癌物质、酶抑制剂、激活剂和离子通道试剂。LC Labs公司不但拥有大规模的制备液相色谱纯化能力，也开发和优化了大量的具有自主知识产权的低成本高纯度生成方法，其生产的小分子试剂纯度高、价格低和销量大。1980年，LC Labs是PMA（佛波醇12-豆蔻酸 13醋酸；TPA）的全球主要生产商，36年来的销售量超过150,000瓶；1989年为研究试剂市场提供第一个纯度高价格低的毒萝卜素；1990年提供第一个纯度高价格低的冈田酸；1991年提供第一个纯度高价格低的花萼海绵诱癌素A，并且持续是这种广泛使用的磷酸酶抑制剂的全球主要生产商；1995年提供第一个异构体级别纯度的低价格Gö 6976；1996年提供第一个纯度高价格低的罗霉素A1；2002年提供第一个纯度高价格低的雷帕霉素（抗真菌抗生素）；同年，提供第一个纯度高、价格低的FK-506；2003年提供第一个纯度高价格低的来普霉素B；2004年提供第一个纯度高价格低的星孢菌素；同年，提供第一个纯度高价格低的环巴胺；2007年，LC Labs公司为临床前肿瘤相关研究引入第一组纯度高价格低的常用蛋白激酶抑制剂。
联络我们
